ProKidney Corporation, often abbreviated as PROK, is an innovative biotechnology company dedicated to revolutionizing the treatment and management of kidney disease. The company, rooted in cutting-edge science and technology, is focused on the development of novel, potentially curative treatments for various kidney disorders.
PRIMARY FUNCTION:
The primary function of PROK is to redefine therapeutic approaches related to kidney health. It aims to develop groundbreaking therapies and treatments through rigorous research and development, with a particular focus targeting the primary causes of kidney diseases, including chronic kidney disease (CKD) and end-stage renal disease (ESRD).
FUTURE VISION:
PROK continuously strives to improve and enhance human health by creating disruptive technologies. The company's future vision is anchored in its commitment to tackle some of the most challenging health problems related to kidney diseases, hoping to alleviate the burden on millions of patients worldwide affected by these diseases.
INNOVATIVE RESEARCH:
One of the key elements that distinguish PROK is its innovative approach to clinical research. PROK leverages the latest advances in genomics, regenerative medicine, and systems biology to understand the pathological processes that cause kidney diseases at the molecular level. This deep understanding paves the way for the development of next-generation therapies that have the potential to restore kidney function and substantially improve patients' quality of life.
PRODUCT PIPELINE:
PROK's product pipeline includes a wide array of therapeutic candidates that target different aspects of kidney health. Each product candidate is painstakingly developed through a rigorous research process. PROK is known for conducting extensive pre-clinical and clinical trials to ensure that the safety and efficacy of its product candidates meet the highest standards.
COMMUNITY INVOLVEMENT:
PROK is deeply committed to patient engagement and community involvement. The company works closely with patient advocacy groups, medical professionals, and other stakeholders to raise awareness about kidney diseases and forge a collective effort to combat these debilitating conditions.
TEAM AND LEADERSHIP:
PROK's innovative vision is led by a group of seasoned professionals with profound knowledge and experience in biomedical research, clinical development, and pharmaceutical industry. They work collectively toward achieving the company’s shared mission.
In summary, ProKidney Corporation (PROK) is a leading light in nephrology, striving to improve the livelihoods of those living with kidney disease through innovative treatments and therapies. By harnessing cutting-edge science and technology, PROK aims to transform the way we understand and treat kidney diseases, with the hope of providing a cure in the future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
ProKidney Corp. announced an Open Market Sale Agreement with Jefferies LLC, allowing the company to sell up to $200 million of Class A common stock through at-the-market offerings. This agreement is contingent on a Form S-3 shelf registration statement becoming effective. Jefferies LLC will serve as the sales agent and receive a commission of up to 3.0% of the gross proceeds.
ProKidney Director Brian JG Pereira sold his entire holding of Class A Common Stock over three consecutive trading days, from August 18 to August 20, 2026. These transactions, both direct and indirect through a trust, were open-market sales. Following these sales, Pereira holds no shares in ProKidney Corp.
_07_03_2026_03_50_21_133108.jpg)
ProKidney Corp. reported increased net losses and higher R&D expenses for Q2 2026, with a net loss of $(28,422) thousand compared to $(16,552) thousand in Q2 2025. Total operating expenses rose to $48,523 thousand, driven by a significant increase in research and development costs. The company's cash and marketable securities also saw a notable decrease from December 31, 2025, reflecting continued investment in its pipeline.